Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2005 2
2006 2
2008 1
2009 1
2010 1
2011 1
2012 1
2013 1
2014 2
2015 2
2016 1
2017 2
2018 3
2019 1
2020 2
2021 1
2022 1
2023 2
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon SS, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O'Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P; POLLUX Investigators. Dimopoulos MA, et al. N Engl J Med. 2016 Oct 6;375(14):1319-1331. doi: 10.1056/NEJMoa1607751. N Engl J Med. 2016. PMID: 27705267 Free article. Clinical Trial.
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.
Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Cavalli F; LYM-3002 investigators. Robak T, et al. Lancet Oncol. 2018 Nov;19(11):1449-1458. doi: 10.1016/S1470-2045(18)30685-5. Epub 2018 Oct 19. Lancet Oncol. 2018. PMID: 30348538 Clinical Trial.
COVID-19, impact on myeloma patients.
Dufour I, Raedemaeker J, Andreozzi F, Verstraete G, Bailly S, Delforge M, Storms P, Jacquy C, Van de Velde A, Mineur P, Lejeune M, Bauwens D, Van Obbergh F, Kentos A, Nguyen J, Fostier K, De Weweire A, Meuleman N, Vekemans MC. Dufour I, et al. Among authors: van de velde a. Ann Hematol. 2020 Aug;99(8):1947-1949. doi: 10.1007/s00277-020-04147-7. Epub 2020 Jun 23. Ann Hematol. 2020. PMID: 32577846 Free PMC article. No abstract available.
Mycosis fungoides of the vulva.
Tjalma WAA, Janssens M, Dam K, Najim O, de Velde AV, Huizing M, Berneman Z, Schroyens W. Tjalma WAA, et al. Among authors: de velde av. North Clin Istanb. 2020 Nov 23;8(1):101-105. doi: 10.14744/nci.2020.12129. eCollection 2021. North Clin Istanb. 2020. PMID: 33623880 Free PMC article.
Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice.
Delforge M, Vekemans MC, Depaus J, Meuleman N, Van de Velde A, Vande Broek I, Vandervennet S, Van Hoorenbeeck S, Moorkens E, Strens D, Diels J, Ghilotti F, Haefliger B, Dalhuisen S, Deraedt W, Anguille S. Delforge M, et al. Among authors: van de velde a. Hemasphere. 2022 Nov 29;6(12):e813. doi: 10.1097/HS9.0000000000000813. eCollection 2022 Dec. Hemasphere. 2022. PMID: 36479545 Free PMC article. No abstract available.
Real-life data of luspatercept in lower-risk myelodysplastic syndromes advocate new research objectives.
Heyrman B, Meers S, Sid S, Put N, Theunissen K, Van Eygen K, De Beule N, Clauwaert M, Maes H, Salembier A, Lemmens J, Velde AV, Selleslag D, Bouziotis J, De Becker A, Anguille S. Heyrman B, et al. Among authors: velde av. EJHaem. 2024 Oct 4;5(5):1096-1099. doi: 10.1002/jha2.1027. eCollection 2024 Oct. EJHaem. 2024. PMID: 39415916 Free PMC article. No abstract available.
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Alexeeva J, Pereira J, Drach J, Mayer J, Hong X, Okamoto R, Pei L, Rooney B, van de Velde H, Cavalli F; LYM-3002 Investigators. Robak T, et al. N Engl J Med. 2015 Mar 5;372(10):944-53. doi: 10.1056/NEJMoa1412096. N Engl J Med. 2015. PMID: 25738670 Free article. Clinical Trial.
Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van de Velde A, van Vliet H. Michiels JJ, et al. Among authors: van de velde a. Clin Appl Thromb Hemost. 2006 Jul;12(3):277-95. doi: 10.1177/1076029606291401. Clin Appl Thromb Hemost. 2006. PMID: 16959681 Free article. Review.
29 results